DOI: 10.12890/2026_005984

Unexpected large-vessel vasculitis in colon adenocarcinoma treated with bevacizumab

Authors

  • Daniela Ribeiro Alves Department of Internal Medicine, Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal
  • Cátia Barra Department of Internal Medicine, Unidade Local de Coimbra, Coimbra, Portugal
  • João Fonseca Department of Internal Medicine, Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal
  • João Pedro Gomes Department of Internal Medicine, Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal
  • Ana Borges Department of Internal Medicine, Unidade Local de Coimbra, Coimbra, Portugal

dralves94@gmail.com

Keywords

Bevacizumab, large-vessel vasculitis, aortitis, colon adenocarcinoma, pharmacovigilance

Abstract

Large-vessel vasculitis is a rare inflammatory disorder affecting the aorta and its major branches and may, in rare cases, be drug-induced. The association with bevacizumab is highly unusual, with only 2 reported cases, both in combination therapy with granulocyte colony-stimulating factor. We report the case of a 47-year-old man with metastatic colon adenocarcinoma treated with chemotherapy and bevacizumab, who was subsequently diagnosed with inflammation of the ascending and descending thoracic aorta and the aortic arch, consistent with large-vessel vasculitis. This is the first documented case of aortitis associated solely with bevacizumab. Although rare, clinical suspicion and early diagnosis are essential, given the potential for severe complications. Imaging plays a pivotal role, particularly in the absence of suggestive clinical features.

View the entire article

Downloads

References

  1. Taimen K, Heino S, Kohonen I, Relas H, Huovinen R, Hänninen A, et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. Rheumatol Adv Pract 2020;4:rkaa004. doi: 10.1093/rap/rkaa004
  2. Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor MJ; French Network of Pharmacovigilance Centers. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol 2012;68:1103-1107. doi: 10.1007/s00228-012-1232-7
  3. Murakami S, Saito H, Ohe M, Kondo T, Oshita F, Yamada K. Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy. Intern Med 2013;52:589-591. doi: 10.2169/internalmedicine.52.6632
  4. Adiga GU, Elkadi D, Malik SK, Fitzpatrick JD, Madajewicz S. Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Investig 2009;29:821-825. doi: 10.2165/11530790-000000000-00000
  5. Hiranuma K, Kusunoki S, Fujino K, Hirayama T, Ota T, Terao Y. Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy. Taiwan J Obstet Gynecol 2018;57:750-752. doi: 10.1016/j.tjog.2018.08.026
  6. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9. doi: 10.1093/jnci/djm086. Erratum in: J Natl Cancer Inst 2008;100:156. Erratum in: J Natl Cancer Inst 2008;100:685.
  7. Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, et al. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. doi: 10.1038/s41572-021-00327-5.
  8. Lensen KD, Voskuyl AE, Comans EF, van der Laken CJ, Smulders YM. Extracranial giant cell arteritis: A narrative review. Neth J Med 2016;74:182-192.

Published

2026-01-13

Issue

Vol. 13 No. 3 (2026)

Categories

How to Cite

1.
Ribeiro Alves D, Barra C, Fonseca J, Gomes JP, Borges A. Unexpected large-vessel vasculitis in colon adenocarcinoma treated with bevacizumab. EJCRIM [Internet]. 2026 Jan. 13 [cited 2026 Nov. 3];13(3). Available from: https://ejcrim.com/index.php/ejcrim/article/view/5984

Most read articles by the same author(s)